[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fZvfg0bp74gL3jj9ce4XYXfV-3LBT51fFAjUQh6gZKY0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":83,"rows":90},"Ionis Pharmaceuticals, Inc.",[4],116,false,22,24,13570,13,5,[14,17,20,22,24,26,28,31],{"name":15,"count":16},"Type 2 Diabetes Mellitus",10,{"name":18,"count":19},"Hypertriglyceridemia",6,{"name":21,"count":12},"Severe Hypertriglyceridemia",{"name":23,"count":12},"Hereditary Angioedema",{"name":25,"count":12},"Familial Chylomicronemia Syndrome",{"name":27,"count":12},"Healthy Volunteers",{"name":29,"count":30},"Healthy Participants",4,{"name":32,"count":30},"Cytomegalovirus Retinitis",[34,39,44,49,54,59,64,69,73,78],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT05143957","A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera","2025-06-26","sapablursen",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT04849741","A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD)","2025-08-22","zilganersen",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT04136171","CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)","2026-04","Eplontersen",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT04768972","FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)","2026-06","ION363",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT05392114","A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)","2026-12","Donidalorsen",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT06153966","PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717","2027-02","ION717",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT05681351","CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)","2027-03","Olezarsen",{"nctId":70,"briefTitle":71,"date":72,"intervention":68},"NCT05185843","A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen","2027-06",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT06914609","REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome","2027-08","ION582",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT07604974","A Study to Assess the Safety, Tolerability and Efficacy of ION775","2027-09","ION775",[84,85,86,87,88,89],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[91,155,258,292,365,387,415,447,469,489,513,536,560,584,632,678,717,739,757,815,862,892,926,961,995,1028,1053,1077,1103,1121,1139,1163,1190,1208,1226,1253,1271,1296,1321,1348,1366,1391,1415,1440,1465,1488,1510,1533,1558,1587,1605,1623,1641,1659,1682,1708,1726,1751,1774,1800,1825,1850,1868,1891,1917,1942,1968,1992,2017,2041,2064,2089,2114,2138,2156,2180,2204,2227,2251,2274,2299,2322,2340,2365,2415],{"intervention":48,"totalTrials":12,"cells":92},{"EARLY_PHASE1":93,"PHASE1":96,"PHASE2":107,"PHASE3":109,"PHASE4":151,"NA":153},{"trials":94,"activeCount":95},[],0,{"trials":97,"activeCount":95},[98],{"nctId":99,"briefTitle":100,"status":101,"phases":102,"primaryCompletion":103,"completion":103,"start":104,"enrollment":9,"conditions":105,"interventions":106},"NCT04302064","A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending and Multiple Doses of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Healthy Japanese Participants","COMPLETED",[85],"2020-09-10","2020-04-23",[29],[48],{"trials":108,"activeCount":95},[],{"trials":110,"activeCount":150,"soonestReadout":47},[111,120,130,139],{"nctId":45,"briefTitle":46,"status":112,"phases":113,"primaryCompletion":47,"completion":114,"start":115,"enrollment":116,"conditions":117,"interventions":119},"ACTIVE_NOT_RECRUITING",[87],"2026-08","2020-03-13",1438,[118],"Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)",[48],{"nctId":121,"briefTitle":122,"status":112,"phases":123,"primaryCompletion":124,"completion":124,"start":125,"enrollment":126,"conditions":127,"interventions":129},"NCT05071300","A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy",[87],"2029-08","2022-01-04",151,[128],"Hereditary Transthyretin-Mediated Amyloid Polyneuropathy",[48],{"nctId":131,"briefTitle":132,"status":133,"phases":134,"primaryCompletion":124,"completion":124,"start":135,"enrollment":136,"conditions":137,"interventions":138},"NCT05667493","An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)","ENROLLING_BY_INVITATION",[87],"2022-11-30",1400,[118],[48],{"nctId":140,"briefTitle":141,"status":101,"phases":142,"primaryCompletion":143,"completion":144,"start":145,"enrollment":146,"conditions":147,"interventions":148},"NCT04136184","NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy",[87],"2023-04-11","2023-07-12","2019-12-11",168,[128],[149,48],"Inotersen",3,{"trials":152,"activeCount":95},[],{"trials":154,"activeCount":95},[],{"intervention":68,"totalTrials":16,"cells":156},{"EARLY_PHASE1":157,"PHASE1":159,"PHASE2":170,"PHASE3":183,"PHASE4":247,"NA":249},{"trials":158,"activeCount":95},[],{"trials":160,"activeCount":95},[161],{"nctId":162,"briefTitle":163,"status":101,"phases":164,"primaryCompletion":165,"completion":165,"start":166,"enrollment":167,"conditions":168,"interventions":169},"NCT05579860","A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healthy Adult Participants",[85],"2023-05-22","2022-10-05",104,[29],[68],{"trials":171,"activeCount":95},[172],{"nctId":173,"briefTitle":174,"status":101,"phases":175,"primaryCompletion":176,"completion":177,"start":178,"enrollment":179,"conditions":180,"interventions":182},"NCT05355402","A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and\u002For With Severe Hypertriglyceridemia",[86],"2023-03-22","2023-12-21","2022-05-09",154,[18,181,21],"Atherosclerotic Cardiovascular Disease",[68],{"trials":184,"activeCount":150,"soonestReadout":67},[185,190,200,212,218,228,238],{"nctId":70,"briefTitle":71,"status":112,"phases":186,"primaryCompletion":72,"completion":72,"start":187,"enrollment":9,"conditions":188,"interventions":189},[87],"2022-02-25",[25],[68],{"nctId":191,"briefTitle":192,"status":101,"phases":193,"primaryCompletion":194,"completion":195,"start":196,"enrollment":197,"conditions":198,"interventions":199},"NCT05552326","A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia",[87],"2024-12-17","2025-09-12","2022-08-31",446,[21],[68],{"nctId":201,"briefTitle":202,"status":101,"phases":203,"primaryCompletion":204,"completion":205,"start":206,"enrollment":207,"conditions":208,"interventions":211},"NCT05610280","A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia",[87],"2024-08-08","2025-06-09","2022-11-21",1478,[18,209,210],"Cardiovascular Diseases","Atherosclerosis",[68],{"nctId":65,"briefTitle":66,"status":112,"phases":213,"primaryCompletion":67,"completion":67,"start":214,"enrollment":215,"conditions":216,"interventions":217},[87],"2022-12-13",885,[21],[68],{"nctId":219,"briefTitle":220,"status":101,"phases":221,"primaryCompletion":222,"completion":223,"start":224,"enrollment":225,"conditions":226,"interventions":227},"NCT05079919","A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia",[87],"2024-10-22","2025-07-08","2021-10-25",617,[21],[68],{"nctId":229,"briefTitle":230,"status":101,"phases":231,"primaryCompletion":232,"completion":233,"start":234,"enrollment":235,"conditions":236,"interventions":237},"NCT04568434","A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)",[87],"2023-07-14","2023-10-17","2020-11-18",66,[25],[68],{"nctId":239,"briefTitle":240,"status":112,"phases":241,"primaryCompletion":242,"completion":242,"start":243,"enrollment":244,"conditions":245,"interventions":246},"NCT05130450","A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)",[87],"2028-02","2021-11-18",60,[25],[68],{"trials":248,"activeCount":95},[],{"trials":250,"activeCount":95},[251],{"nctId":252,"briefTitle":253,"status":254,"phases":255,"conditions":256,"interventions":257},"NCT06360237","Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)","APPROVED_FOR_MARKETING",[],[25],[68],{"intervention":77,"totalTrials":259,"cells":260},2,{"EARLY_PHASE1":261,"PHASE1":263,"PHASE2":265,"PHASE3":279,"PHASE4":288,"NA":290},{"trials":262,"activeCount":95},[],{"trials":264,"activeCount":95},[],{"trials":266,"activeCount":278,"soonestReadout":272},[267],{"nctId":268,"briefTitle":269,"status":270,"phases":271,"primaryCompletion":272,"completion":272,"start":273,"enrollment":274,"conditions":275,"interventions":277},"NCT05127226","HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome","RECRUITING",[85,86],"2029-03","2021-12-22",70,[276],"Angelman Syndrome",[77],1,{"trials":280,"activeCount":278,"soonestReadout":76},[281],{"nctId":74,"briefTitle":75,"status":270,"phases":282,"primaryCompletion":76,"completion":283,"start":284,"enrollment":285,"conditions":286,"interventions":287},[87],"2030-04","2025-06-10",158,[276],[77],{"trials":289,"activeCount":95},[],{"trials":291,"activeCount":95},[],{"intervention":58,"totalTrials":293,"cells":294},7,{"EARLY_PHASE1":295,"PHASE1":297,"PHASE2":308,"PHASE3":329,"PHASE4":354,"NA":356},{"trials":296,"activeCount":95},[],{"trials":298,"activeCount":95},[299],{"nctId":300,"briefTitle":301,"status":101,"phases":302,"primaryCompletion":303,"completion":303,"start":304,"enrollment":305,"conditions":306,"interventions":307},"NCT03263507","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Donidalorsen (IONIS-PKK-LRx) Administered Subcutaneously to Healthy Volunteers",[85],"2018-10-09","2017-08-28",32,[27],[58],{"trials":309,"activeCount":95},[310,319],{"nctId":311,"briefTitle":312,"status":101,"phases":313,"primaryCompletion":314,"completion":314,"start":315,"enrollment":316,"conditions":317,"interventions":318},"NCT04307381","An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema",[86],"2025-01-24","2020-03-31",20,[23],[58],{"nctId":320,"briefTitle":321,"status":101,"phases":322,"primaryCompletion":323,"completion":324,"start":325,"enrollment":326,"conditions":327,"interventions":328},"NCT04030598","A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary Angioedema",[86],"2021-01-04","2021-03-01","2020-01-07",23,[23],[58],{"trials":330,"activeCount":259,"soonestReadout":57},[331,340,349],{"nctId":332,"briefTitle":333,"status":270,"phases":334,"primaryCompletion":335,"completion":335,"start":336,"enrollment":316,"conditions":337,"interventions":339},"NCT07298447","Donidalorsen Treatment in Children With Hereditary Angioedema",[87],"2029-06","2026-04-21",[338],"Hereditary Angioedema (HAE)",[58],{"nctId":341,"briefTitle":342,"status":101,"phases":343,"primaryCompletion":344,"completion":344,"start":345,"enrollment":346,"conditions":347,"interventions":348},"NCT05139810","OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)",[87],"2023-11-09","2021-12-03",91,[23],[58],{"nctId":55,"briefTitle":56,"status":112,"phases":350,"primaryCompletion":57,"completion":67,"start":351,"enrollment":179,"conditions":352,"interventions":353},[87],"2022-07-13",[23],[58],{"trials":355,"activeCount":95},[],{"trials":357,"activeCount":95},[358],{"nctId":359,"briefTitle":360,"status":361,"phases":362,"conditions":363,"interventions":364},"NCT06415448","Donidalorsen Expanded Access Program for Patients With Hereditary Angioedema","AVAILABLE",[],[23],[58],{"intervention":53,"totalTrials":278,"cells":366},{"EARLY_PHASE1":367,"PHASE1":369,"PHASE2":371,"PHASE3":373,"PHASE4":383,"NA":385},{"trials":368,"activeCount":95},[],{"trials":370,"activeCount":95},[],{"trials":372,"activeCount":95},[],{"trials":374,"activeCount":278,"soonestReadout":52},[375],{"nctId":50,"briefTitle":51,"status":112,"phases":376,"primaryCompletion":52,"completion":377,"start":378,"enrollment":379,"conditions":380,"interventions":382},[87],"2028-03","2021-06-14",89,[381],"Amyotrophic Lateral Sclerosis",[53],{"trials":384,"activeCount":95},[],{"trials":386,"activeCount":95},[],{"intervention":43,"totalTrials":259,"cells":388},{"EARLY_PHASE1":389,"PHASE1":391,"PHASE2":393,"PHASE3":395,"PHASE4":405,"NA":407},{"trials":390,"activeCount":95},[],{"trials":392,"activeCount":95},[],{"trials":394,"activeCount":95},[],{"trials":396,"activeCount":278,"soonestReadout":42},[397],{"nctId":40,"briefTitle":41,"status":112,"phases":398,"primaryCompletion":42,"completion":399,"start":400,"enrollment":401,"conditions":402,"interventions":404},[87],"2029-09","2021-06-01",54,[403],"Alexander Disease",[43],{"trials":406,"activeCount":95},[],{"trials":408,"activeCount":95},[409],{"nctId":410,"briefTitle":411,"status":361,"phases":412,"conditions":413,"interventions":414},"NCT07487389","Zilganersen Expanded Access Program for Individuals With Alexander Disease",[],[403],[43],{"intervention":38,"totalTrials":259,"cells":416},{"EARLY_PHASE1":417,"PHASE1":419,"PHASE2":421,"PHASE3":441,"PHASE4":443,"NA":445},{"trials":418,"activeCount":95},[],{"trials":420,"activeCount":95},[],{"trials":422,"activeCount":278,"soonestReadout":37},[423,434],{"nctId":424,"briefTitle":425,"status":426,"phases":427,"primaryCompletion":428,"completion":428,"start":429,"enrollment":430,"conditions":431,"interventions":433},"NCT04059406","Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx)","TERMINATED",[86],"2023-03-28","2020-09-24",29,[432],"Beta Thalassemia Intermedia",[38],{"nctId":35,"briefTitle":36,"status":112,"phases":435,"primaryCompletion":37,"completion":52,"start":436,"enrollment":437,"conditions":438,"interventions":440},[86],"2021-12-30",50,[439],"Phlebotomy Dependent Polycythemia Vera",[38],{"trials":442,"activeCount":95},[],{"trials":444,"activeCount":95},[],{"trials":446,"activeCount":95},[],{"intervention":63,"totalTrials":278,"cells":448},{"EARLY_PHASE1":449,"PHASE1":451,"PHASE2":453,"PHASE3":463,"PHASE4":465,"NA":467},{"trials":450,"activeCount":95},[],{"trials":452,"activeCount":95},[],{"trials":454,"activeCount":278,"soonestReadout":62},[455],{"nctId":60,"briefTitle":61,"status":270,"phases":456,"primaryCompletion":62,"completion":457,"start":458,"enrollment":459,"conditions":460,"interventions":462},[85,86],"2030-06","2024-01-04",76,[461],"Prion Disease",[63],{"trials":464,"activeCount":95},[],{"trials":466,"activeCount":95},[],{"trials":468,"activeCount":95},[],{"intervention":82,"totalTrials":278,"cells":470},{"EARLY_PHASE1":471,"PHASE1":473,"PHASE2":475,"PHASE3":483,"PHASE4":485,"NA":487},{"trials":472,"activeCount":95},[],{"trials":474,"activeCount":95},[],{"trials":476,"activeCount":278,"soonestReadout":81},[477],{"nctId":79,"briefTitle":80,"status":270,"phases":478,"primaryCompletion":81,"completion":377,"start":479,"enrollment":480,"conditions":481,"interventions":482},[86],"2026-05",72,[18,21],[82],{"trials":484,"activeCount":95},[],{"trials":486,"activeCount":95},[],{"trials":488,"activeCount":95},[],{"intervention":490,"totalTrials":278,"cells":491},"ION440",{"EARLY_PHASE1":492,"PHASE1":494,"PHASE2":496,"PHASE3":507,"PHASE4":509,"NA":511},{"trials":493,"activeCount":95},[],{"trials":495,"activeCount":95},[],{"trials":497,"activeCount":278,"soonestReadout":81},[498],{"nctId":499,"briefTitle":500,"status":270,"phases":501,"primaryCompletion":81,"completion":283,"start":502,"enrollment":503,"conditions":504,"interventions":506},"NCT06430385","ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)",[85,86],"2024-10-21",48,[505],"Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome",[490],{"trials":508,"activeCount":95},[],{"trials":510,"activeCount":95},[],{"trials":512,"activeCount":95},[],{"intervention":514,"totalTrials":278,"cells":515},"ION337",{"EARLY_PHASE1":516,"PHASE1":518,"PHASE2":520,"PHASE3":530,"PHASE4":532,"NA":534},{"trials":517,"activeCount":95},[],{"trials":519,"activeCount":95},[],{"trials":521,"activeCount":278,"soonestReadout":526},[522],{"nctId":523,"briefTitle":524,"status":270,"phases":525,"primaryCompletion":526,"completion":526,"start":47,"enrollment":305,"conditions":527,"interventions":529},"NCT07531745","ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome",[85,86],"2030-12",[528],"Dravet Syndrome",[514],{"trials":531,"activeCount":95},[],{"trials":533,"activeCount":95},[],{"trials":535,"activeCount":95},[],{"intervention":537,"totalTrials":278,"cells":538},"ION464",{"EARLY_PHASE1":539,"PHASE1":541,"PHASE2":552,"PHASE3":554,"PHASE4":556,"NA":558},{"trials":540,"activeCount":95},[],{"trials":542,"activeCount":278,"soonestReadout":81},[543],{"nctId":544,"briefTitle":545,"status":270,"phases":546,"primaryCompletion":81,"completion":81,"start":547,"enrollment":548,"conditions":549,"interventions":551},"NCT04165486","Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)",[85],"2022-07-21",40,[550],"Multiple System Atrophy",[537],{"trials":553,"activeCount":95},[],{"trials":555,"activeCount":95},[],{"trials":557,"activeCount":95},[],{"trials":559,"activeCount":95},[],{"intervention":561,"totalTrials":278,"cells":562},"ION356",{"EARLY_PHASE1":563,"PHASE1":565,"PHASE2":576,"PHASE3":578,"PHASE4":580,"NA":582},{"trials":564,"activeCount":95},[],{"trials":566,"activeCount":278,"soonestReadout":571},[567],{"nctId":568,"briefTitle":569,"status":270,"phases":570,"primaryCompletion":571,"completion":571,"start":572,"enrollment":9,"conditions":573,"interventions":575},"NCT06150716","Orbit Study: A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered ION356 in Participants With Pelizaeus Merzbacher Disease (PMD)",[85],"2028-06","2024-04-10",[574],"Pelizaeus-Merzbacher Disease",[561],{"trials":577,"activeCount":95},[],{"trials":579,"activeCount":95},[],{"trials":581,"activeCount":95},[],{"trials":583,"activeCount":95},[],{"intervention":585,"totalTrials":30,"cells":586},"Alicaforsen",{"EARLY_PHASE1":587,"PHASE1":589,"PHASE2":591,"PHASE3":610,"PHASE4":628,"NA":630},{"trials":588,"activeCount":95},[],{"trials":590,"activeCount":95},[],{"trials":592,"activeCount":95},[593,602],{"nctId":594,"briefTitle":595,"status":101,"phases":596,"primaryCompletion":597,"completion":597,"start":598,"conditions":599,"interventions":601},"NCT00063830","ISIS 2302-CS27, A 6-Week, Placebo-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis.",[86],"2004-10-11","2003-04-03",[600],"Ulcerative Colitis",[585],{"nctId":603,"briefTitle":604,"status":101,"phases":605,"primaryCompletion":606,"completion":606,"start":607,"conditions":608,"interventions":609},"NCT00063414","ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis",[86],"2005-03-24","2002-11-20",[600],[585],{"trials":611,"activeCount":95},[612,621],{"nctId":613,"briefTitle":614,"status":101,"phases":615,"start":616,"enrollment":617,"conditions":618,"interventions":620},"NCT00048295","Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease",[87],"2002-05",150,[619],"Crohn's Disease",[585],{"nctId":622,"briefTitle":614,"status":101,"phases":623,"primaryCompletion":624,"completion":624,"start":625,"enrollment":617,"conditions":626,"interventions":627},"NCT00048113",[87],"2002-04-27","2001-01-10",[619],[585],{"trials":629,"activeCount":95},[],{"trials":631,"activeCount":95},[],{"intervention":633,"totalTrials":150,"cells":634},"Volanesorsen",{"EARLY_PHASE1":635,"PHASE1":637,"PHASE2":650,"PHASE3":652,"PHASE4":674,"NA":676},{"trials":636,"activeCount":95},[],{"trials":638,"activeCount":95},[639],{"nctId":640,"briefTitle":641,"status":101,"phases":642,"primaryCompletion":643,"completion":643,"start":644,"enrollment":645,"conditions":646,"interventions":648},"NCT02910635","A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers",[85],"2016-12-20","2016-09-19",52,[647],"Abnormalities, Cardiovascular",[633,649],"Moxifloxacin",{"trials":651,"activeCount":95},[],{"trials":653,"activeCount":95},[654,664],{"nctId":655,"briefTitle":656,"status":101,"phases":657,"primaryCompletion":658,"completion":659,"start":660,"enrollment":661,"conditions":662,"interventions":663},"NCT02300233","The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia",[87],"2016-07-27","2017-01-24","2015-02-05",114,[18],[633],{"nctId":665,"briefTitle":666,"status":101,"phases":667,"primaryCompletion":668,"completion":669,"start":670,"enrollment":671,"conditions":672,"interventions":673},"NCT02211209","The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome",[87],"2016-12-19","2017-03-28","2014-12",67,[25],[633],{"trials":675,"activeCount":95},[],{"trials":677,"activeCount":95},[],{"intervention":679,"totalTrials":259,"cells":680},"Paclitaxel",{"EARLY_PHASE1":681,"PHASE1":683,"PHASE2":685,"PHASE3":699,"PHASE4":713,"NA":715},{"trials":682,"activeCount":95},[],{"trials":684,"activeCount":95},[],{"trials":686,"activeCount":95},[687],{"nctId":688,"briefTitle":689,"status":101,"phases":690,"primaryCompletion":691,"completion":692,"start":693,"enrollment":6,"conditions":694,"interventions":696},"NCT01234038","Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel",[85,86],"2012-10","2013-01","2010-11",[695],"Non-small Cell Lung Cancer",[697,697,697,679,698],"ISIS EIF4E Rx","Carboplatin",{"trials":700,"activeCount":95},[701],{"nctId":702,"briefTitle":703,"status":101,"phases":704,"primaryCompletion":705,"completion":705,"start":706,"conditions":707,"interventions":709},"NCT00017407","Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer",[87],"2002-09-09","2000-10-13",[708],"Lung Cancer",[710,711,712],"ISIS 3521","carboplatin","paclitaxel",{"trials":714,"activeCount":95},[],{"trials":716,"activeCount":95},[],{"intervention":698,"totalTrials":259,"cells":718},{"EARLY_PHASE1":719,"PHASE1":721,"PHASE2":723,"PHASE3":729,"PHASE4":735,"NA":737},{"trials":720,"activeCount":95},[],{"trials":722,"activeCount":95},[],{"trials":724,"activeCount":95},[725],{"nctId":688,"briefTitle":689,"status":101,"phases":726,"primaryCompletion":691,"completion":692,"start":693,"enrollment":6,"conditions":727,"interventions":728},[85,86],[695],[697,697,697,679,698],{"trials":730,"activeCount":95},[731],{"nctId":702,"briefTitle":703,"status":101,"phases":732,"primaryCompletion":705,"completion":705,"start":706,"conditions":733,"interventions":734},[87],[708],[710,711,712],{"trials":736,"activeCount":95},[],{"trials":738,"activeCount":95},[],{"intervention":710,"totalTrials":278,"cells":740},{"EARLY_PHASE1":741,"PHASE1":743,"PHASE2":745,"PHASE3":747,"PHASE4":753,"NA":755},{"trials":742,"activeCount":95},[],{"trials":744,"activeCount":95},[],{"trials":746,"activeCount":95},[],{"trials":748,"activeCount":95},[749],{"nctId":702,"briefTitle":703,"status":101,"phases":750,"primaryCompletion":705,"completion":705,"start":706,"conditions":751,"interventions":752},[87],[708],[710,711,712],{"trials":754,"activeCount":95},[],{"trials":756,"activeCount":95},[],{"intervention":758,"totalTrials":12,"cells":759},"ISIS 113715",{"EARLY_PHASE1":760,"PHASE1":762,"PHASE2":772,"PHASE3":809,"PHASE4":811,"NA":813},{"trials":761,"activeCount":95},[],{"trials":763,"activeCount":95},[764],{"nctId":765,"briefTitle":766,"status":101,"phases":767,"completion":768,"start":769,"enrollment":16,"conditions":770,"interventions":771},"NCT00365781","Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715",[85],"2006-09","2006-08",[15],[758],{"trials":773,"activeCount":95},[774,784,791,801],{"nctId":775,"briefTitle":776,"status":777,"phases":778,"primaryCompletion":779,"completion":780,"start":781,"enrollment":95,"conditions":782,"interventions":783},"NCT00327626","Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea","WITHDRAWN",[86],"2007-02-01","2007-03-01","2006-05-01",[15],[758],{"nctId":785,"briefTitle":786,"status":426,"phases":787,"primaryCompletion":780,"completion":780,"start":788,"enrollment":259,"conditions":789,"interventions":790},"NCT00330200","Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics",[86],"2005-11-01",[15],[758],{"nctId":792,"briefTitle":793,"status":101,"phases":794,"primaryCompletion":795,"completion":796,"start":797,"enrollment":798,"conditions":799,"interventions":800},"NCT00455598","Placebo Controlled, Dose Escalation Study in Subjects With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea",[86],"2009-03","2009-05","2007-02",88,[15],[758],{"nctId":802,"briefTitle":803,"status":101,"phases":804,"completion":769,"start":805,"enrollment":806,"conditions":807,"interventions":808},"NCT00330330","Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior Treatment",[86],"2003-02",96,[15],[758],{"trials":810,"activeCount":95},[],{"trials":812,"activeCount":95},[],{"trials":814,"activeCount":95},[],{"intervention":816,"totalTrials":150,"cells":817},"IONIS-FB-LRx",{"EARLY_PHASE1":818,"PHASE1":820,"PHASE2":822,"PHASE3":856,"PHASE4":858,"NA":860},{"trials":819,"activeCount":95},[],{"trials":821,"activeCount":95},[],{"trials":823,"activeCount":95},[824,835,845],{"nctId":825,"briefTitle":826,"status":777,"phases":827,"primaryCompletion":828,"completion":828,"start":829,"enrollment":95,"conditions":830,"interventions":833},"NCT03446144","Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)",[86],"2018-10-10","2018-03-16",[831,832],"Geographic Atrophy","Age Related Macular Degeneration",[834],"IONIS-FB-Lrx",{"nctId":836,"briefTitle":837,"status":101,"phases":838,"primaryCompletion":839,"completion":840,"start":841,"enrollment":326,"conditions":842,"interventions":844},"NCT04014335","A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy",[86],"2024-02-08","2024-04-11","2019-12-04",[843],"Primary IgA Nephropathy",[816],{"nctId":846,"briefTitle":847,"status":101,"phases":848,"primaryCompletion":849,"completion":850,"start":851,"enrollment":852,"conditions":853,"interventions":855},"NCT03815825","GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)",[86],"2024-04-18","2024-06-12","2019-03-04",332,[854,831],"Macular Degeneration",[816],{"trials":857,"activeCount":95},[],{"trials":859,"activeCount":95},[],{"trials":861,"activeCount":95},[],{"intervention":697,"totalTrials":259,"cells":863},{"EARLY_PHASE1":864,"PHASE1":866,"PHASE2":868,"PHASE3":886,"PHASE4":888,"NA":890},{"trials":865,"activeCount":95},[],{"trials":867,"activeCount":95},[],{"trials":869,"activeCount":95},[870,882],{"nctId":871,"briefTitle":872,"status":101,"phases":873,"primaryCompletion":874,"completion":875,"start":693,"enrollment":876,"conditions":877,"interventions":879},"NCT01234025","Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)",[85,86],"2013-05","2013-12",113,[878],"Castrate-Resistant Prostate Cancer",[697,697,697,880,881],"Prednisone","Docetaxel",{"nctId":688,"briefTitle":689,"status":101,"phases":883,"primaryCompletion":691,"completion":692,"start":693,"enrollment":6,"conditions":884,"interventions":885},[85,86],[695],[697,697,697,679,698],{"trials":887,"activeCount":95},[],{"trials":889,"activeCount":95},[],{"trials":891,"activeCount":95},[],{"intervention":893,"totalTrials":259,"cells":894},"ISIS 757456",{"EARLY_PHASE1":895,"PHASE1":897,"PHASE2":899,"PHASE3":920,"PHASE4":922,"NA":924},{"trials":896,"activeCount":95},[],{"trials":898,"activeCount":95},[],{"trials":900,"activeCount":95},[901,911],{"nctId":902,"briefTitle":903,"status":101,"phases":904,"primaryCompletion":905,"completion":905,"start":906,"enrollment":907,"conditions":908,"interventions":910},"NCT03714776","A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Participants With Controlled Blood Pressure",[86],"2019-11-13","2019-01-03",25,[909],"Mild Hypertension",[893],{"nctId":912,"briefTitle":913,"status":101,"phases":914,"primaryCompletion":915,"completion":915,"start":905,"enrollment":916,"conditions":917,"interventions":919},"NCT04083222","A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx",[86],"2020-07-20",26,[918],"Hypertension",[893],{"trials":921,"activeCount":95},[],{"trials":923,"activeCount":95},[],{"trials":925,"activeCount":95},[],{"intervention":927,"totalTrials":259,"cells":928},"IONIS-AGT-LRx",{"EARLY_PHASE1":929,"PHASE1":931,"PHASE2":933,"PHASE3":955,"PHASE4":957,"NA":959},{"trials":930,"activeCount":95},[],{"trials":932,"activeCount":95},[],{"trials":934,"activeCount":95},[935,945],{"nctId":936,"briefTitle":937,"status":101,"phases":938,"primaryCompletion":939,"completion":940,"start":941,"enrollment":480,"conditions":942,"interventions":944},"NCT04836182","A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction",[86],"2022-10-19","2023-01-11","2021-06-08",[943],"Chronic Heart Failure With Reduced Ejection Fraction",[927],{"nctId":946,"briefTitle":947,"status":101,"phases":948,"primaryCompletion":949,"completion":950,"start":951,"enrollment":952,"conditions":953,"interventions":954},"NCT04714320","A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure",[86],"2022-06-29","2022-10-03","2021-04-28",160,[918],[927],{"trials":956,"activeCount":95},[],{"trials":958,"activeCount":95},[],{"trials":960,"activeCount":95},[],{"intervention":962,"totalTrials":259,"cells":963},"ISIS 416858",{"EARLY_PHASE1":964,"PHASE1":966,"PHASE2":968,"PHASE3":989,"PHASE4":991,"NA":993},{"trials":965,"activeCount":95},[],{"trials":967,"activeCount":95},[],{"trials":969,"activeCount":95},[970,980],{"nctId":971,"briefTitle":972,"status":101,"phases":973,"primaryCompletion":974,"completion":974,"start":975,"enrollment":976,"conditions":977,"interventions":979},"NCT03358030","A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis",[86],"2019-07-10","2017-12-26",213,[978],"End-stage Renal Disease (ESRD)",[962],{"nctId":981,"briefTitle":982,"status":101,"phases":983,"primaryCompletion":984,"completion":984,"start":985,"enrollment":986,"conditions":987,"interventions":988},"NCT02553889","A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis",[86],"2016-11","2015-10",49,[978],[962],{"trials":990,"activeCount":95},[],{"trials":992,"activeCount":95},[],{"trials":994,"activeCount":95},[],{"intervention":996,"totalTrials":259,"cells":997},"ION904",{"EARLY_PHASE1":998,"PHASE1":1000,"PHASE2":1011,"PHASE3":1022,"PHASE4":1024,"NA":1026},{"trials":999,"activeCount":95},[],{"trials":1001,"activeCount":95},[1002],{"nctId":1003,"briefTitle":1004,"status":101,"phases":1005,"primaryCompletion":1006,"completion":1007,"start":1008,"enrollment":548,"conditions":1009,"interventions":1010},"NCT04731623","A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION904",[85],"2021-08-12","2021-09-11","2021-02-26",[27],[996],{"trials":1012,"activeCount":95},[1013],{"nctId":1014,"briefTitle":1015,"status":101,"phases":1016,"primaryCompletion":1017,"completion":1018,"start":1019,"enrollment":503,"conditions":1020,"interventions":1021},"NCT05314439","A Study to Assess the Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of ION904 in Participants With Uncontrolled Hypertension",[86],"2023-01-31","2023-02-15","2022-04-29",[918],[996],{"trials":1023,"activeCount":95},[],{"trials":1025,"activeCount":95},[],{"trials":1027,"activeCount":95},[],{"intervention":1029,"totalTrials":278,"cells":1030},"ION224",{"EARLY_PHASE1":1031,"PHASE1":1033,"PHASE2":1035,"PHASE3":1047,"PHASE4":1049,"NA":1051},{"trials":1032,"activeCount":95},[],{"trials":1034,"activeCount":95},[],{"trials":1036,"activeCount":95},[1037],{"nctId":1038,"briefTitle":1039,"status":101,"phases":1040,"primaryCompletion":1041,"completion":1042,"start":1043,"enrollment":952,"conditions":1044,"interventions":1046},"NCT04932512","A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224",[86],"2024-01-10","2024-02-28","2021-06-17",[1045],"Steatohepatitis, Nonalcoholic",[1029],{"trials":1048,"activeCount":95},[],{"trials":1050,"activeCount":95},[],{"trials":1052,"activeCount":95},[],{"intervention":1054,"totalTrials":278,"cells":1055},"ISIS 14803",{"EARLY_PHASE1":1056,"PHASE1":1058,"PHASE2":1060,"PHASE3":1071,"PHASE4":1073,"NA":1075},{"trials":1057,"activeCount":95},[],{"trials":1059,"activeCount":95},[],{"trials":1061,"activeCount":95},[1062],{"nctId":1063,"briefTitle":1064,"status":101,"phases":1065,"primaryCompletion":1066,"completion":1066,"start":1067,"conditions":1068,"interventions":1070},"NCT00035945","ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections",[86],"2004-05-01","2001-10-01",[1069],"Hepatitis C, Chronic",[1054],{"trials":1072,"activeCount":95},[],{"trials":1074,"activeCount":95},[],{"trials":1076,"activeCount":95},[],{"intervention":1078,"totalTrials":278,"cells":1079},"ION-827359",{"EARLY_PHASE1":1080,"PHASE1":1082,"PHASE2":1084,"PHASE3":1097,"PHASE4":1099,"NA":1101},{"trials":1081,"activeCount":95},[],{"trials":1083,"activeCount":95},[],{"trials":1085,"activeCount":95},[1086],{"nctId":1087,"briefTitle":1088,"status":426,"phases":1089,"primaryCompletion":1090,"completion":1091,"start":1092,"enrollment":244,"conditions":1093,"interventions":1096},"NCT04441788","A Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Participants With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis (CB)",[86],"2021-04-27","2021-08-09","2020-12-22",[1094,1095],"Chronic Bronchitis","Chronic Obstructive Pulmonary Disease",[1078,1078],{"trials":1098,"activeCount":95},[],{"trials":1100,"activeCount":95},[],{"trials":1102,"activeCount":95},[],{"intervention":880,"totalTrials":278,"cells":1104},{"EARLY_PHASE1":1105,"PHASE1":1107,"PHASE2":1109,"PHASE3":1115,"PHASE4":1117,"NA":1119},{"trials":1106,"activeCount":95},[],{"trials":1108,"activeCount":95},[],{"trials":1110,"activeCount":95},[1111],{"nctId":871,"briefTitle":872,"status":101,"phases":1112,"primaryCompletion":874,"completion":875,"start":693,"enrollment":876,"conditions":1113,"interventions":1114},[85,86],[878],[697,697,697,880,881],{"trials":1116,"activeCount":95},[],{"trials":1118,"activeCount":95},[],{"trials":1120,"activeCount":95},[],{"intervention":881,"totalTrials":278,"cells":1122},{"EARLY_PHASE1":1123,"PHASE1":1125,"PHASE2":1127,"PHASE3":1133,"PHASE4":1135,"NA":1137},{"trials":1124,"activeCount":95},[],{"trials":1126,"activeCount":95},[],{"trials":1128,"activeCount":95},[1129],{"nctId":871,"briefTitle":872,"status":101,"phases":1130,"primaryCompletion":874,"completion":875,"start":693,"enrollment":876,"conditions":1131,"interventions":1132},[85,86],[878],[697,697,697,880,881],{"trials":1134,"activeCount":95},[],{"trials":1136,"activeCount":95},[],{"trials":1138,"activeCount":95},[],{"intervention":1140,"totalTrials":278,"cells":1141},"ISIS 104838",{"EARLY_PHASE1":1142,"PHASE1":1144,"PHASE2":1146,"PHASE3":1157,"PHASE4":1159,"NA":1161},{"trials":1143,"activeCount":95},[],{"trials":1145,"activeCount":95},[],{"trials":1147,"activeCount":95},[1148],{"nctId":1149,"briefTitle":1150,"status":101,"phases":1151,"primaryCompletion":1152,"completion":1152,"start":1153,"enrollment":952,"conditions":1154,"interventions":1156},"NCT00048321","ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis",[86],"2003-02-01","2002-01-01",[1155],"Rheumatoid Arthritis",[1140],{"trials":1158,"activeCount":95},[],{"trials":1160,"activeCount":95},[],{"trials":1162,"activeCount":95},[],{"intervention":1164,"totalTrials":278,"cells":1165},"ISIS-FXIRx Dose #2",{"EARLY_PHASE1":1166,"PHASE1":1168,"PHASE2":1170,"PHASE3":1184,"PHASE4":1186,"NA":1188},{"trials":1167,"activeCount":95},[],{"trials":1169,"activeCount":95},[],{"trials":1171,"activeCount":95},[1172],{"nctId":1173,"briefTitle":1174,"status":101,"phases":1175,"primaryCompletion":1176,"completion":1177,"start":691,"enrollment":1178,"conditions":1179,"interventions":1181},"NCT01713361","Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS-FXIRx in Total Knee Arthroplasty",[86],"2014-05","2014-08",315,[1180],"Venous Thromboembolism",[1164,1182,1183],"ISIS-FXIRx Dose #3","Enoxaparin",{"trials":1185,"activeCount":95},[],{"trials":1187,"activeCount":95},[],{"trials":1189,"activeCount":95},[],{"intervention":1182,"totalTrials":278,"cells":1191},{"EARLY_PHASE1":1192,"PHASE1":1194,"PHASE2":1196,"PHASE3":1202,"PHASE4":1204,"NA":1206},{"trials":1193,"activeCount":95},[],{"trials":1195,"activeCount":95},[],{"trials":1197,"activeCount":95},[1198],{"nctId":1173,"briefTitle":1174,"status":101,"phases":1199,"primaryCompletion":1176,"completion":1177,"start":691,"enrollment":1178,"conditions":1200,"interventions":1201},[86],[1180],[1164,1182,1183],{"trials":1203,"activeCount":95},[],{"trials":1205,"activeCount":95},[],{"trials":1207,"activeCount":95},[],{"intervention":1183,"totalTrials":278,"cells":1209},{"EARLY_PHASE1":1210,"PHASE1":1212,"PHASE2":1214,"PHASE3":1220,"PHASE4":1222,"NA":1224},{"trials":1211,"activeCount":95},[],{"trials":1213,"activeCount":95},[],{"trials":1215,"activeCount":95},[1216],{"nctId":1173,"briefTitle":1174,"status":101,"phases":1217,"primaryCompletion":1176,"completion":1177,"start":691,"enrollment":1178,"conditions":1218,"interventions":1219},[86],[1180],[1164,1182,1183],{"trials":1221,"activeCount":95},[],{"trials":1223,"activeCount":95},[],{"trials":1225,"activeCount":95},[],{"intervention":1227,"totalTrials":278,"cells":1228},"ISIS-GCGRRx- Dose Level 1",{"EARLY_PHASE1":1229,"PHASE1":1231,"PHASE2":1233,"PHASE3":1247,"PHASE4":1249,"NA":1251},{"trials":1230,"activeCount":95},[],{"trials":1232,"activeCount":95},[],{"trials":1234,"activeCount":95},[1235],{"nctId":1236,"briefTitle":1237,"status":101,"phases":1238,"primaryCompletion":1239,"completion":1240,"start":1241,"enrollment":1242,"conditions":1243,"interventions":1245},"NCT02583919","Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 Diabetes",[86],"2016-12-15","2017-05-11","2015-09",79,[1244],"Type 2 Diabetes",[1227,1246],"ISIS-GCGRRx- Dose Level 2",{"trials":1248,"activeCount":95},[],{"trials":1250,"activeCount":95},[],{"trials":1252,"activeCount":95},[],{"intervention":1246,"totalTrials":278,"cells":1254},{"EARLY_PHASE1":1255,"PHASE1":1257,"PHASE2":1259,"PHASE3":1265,"PHASE4":1267,"NA":1269},{"trials":1256,"activeCount":95},[],{"trials":1258,"activeCount":95},[],{"trials":1260,"activeCount":95},[1261],{"nctId":1236,"briefTitle":1237,"status":101,"phases":1262,"primaryCompletion":1239,"completion":1240,"start":1241,"enrollment":1242,"conditions":1263,"interventions":1264},[86],[1244],[1227,1246],{"trials":1266,"activeCount":95},[],{"trials":1268,"activeCount":95},[],{"trials":1270,"activeCount":95},[],{"intervention":1272,"totalTrials":278,"cells":1273},"ISIS-APO(a)Rx",{"EARLY_PHASE1":1274,"PHASE1":1276,"PHASE2":1278,"PHASE3":1290,"PHASE4":1292,"NA":1294},{"trials":1275,"activeCount":95},[],{"trials":1277,"activeCount":95},[],{"trials":1279,"activeCount":95},[1280],{"nctId":1281,"briefTitle":1282,"status":101,"phases":1283,"primaryCompletion":1284,"completion":1284,"start":1285,"enrollment":1286,"conditions":1287,"interventions":1289},"NCT02160899","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx in Participants With High Lipoprotein(a)",[86],"2015-11","2014-06",64,[1288],"Elevated Lipoprotein(a)",[1272],{"trials":1291,"activeCount":95},[],{"trials":1293,"activeCount":95},[],{"trials":1295,"activeCount":95},[],{"intervention":1297,"totalTrials":278,"cells":1298},"ISIS-GCCRRx",{"EARLY_PHASE1":1299,"PHASE1":1301,"PHASE2":1303,"PHASE3":1315,"PHASE4":1317,"NA":1319},{"trials":1300,"activeCount":95},[],{"trials":1302,"activeCount":95},[],{"trials":1304,"activeCount":95},[1305],{"nctId":1306,"briefTitle":1307,"status":101,"phases":1308,"primaryCompletion":1309,"completion":1310,"start":1311,"enrollment":1312,"conditions":1313,"interventions":1314},"NCT01968265","Safety, Tolerability and Efficacy of ISIS-GCCRRx in Type 2 Diabetes",[86],"2015-01","2015-05","2013-10",38,[15],[1297],{"trials":1316,"activeCount":95},[],{"trials":1318,"activeCount":95},[],{"trials":1320,"activeCount":95},[],{"intervention":1322,"totalTrials":278,"cells":1323},"ISIS-PTP1BRx",{"EARLY_PHASE1":1324,"PHASE1":1326,"PHASE2":1328,"PHASE3":1342,"PHASE4":1344,"NA":1346},{"trials":1325,"activeCount":95},[],{"trials":1327,"activeCount":95},[],{"trials":1329,"activeCount":95},[1330],{"nctId":1331,"briefTitle":1332,"status":101,"phases":1333,"primaryCompletion":1334,"completion":1335,"start":1336,"enrollment":1337,"conditions":1338,"interventions":1340},"NCT01918865","Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes",[86],"2014-10","2015-02","2013-08",92,[15,1339],"Obese",[1322,1341],"daily OAD",{"trials":1343,"activeCount":95},[],{"trials":1345,"activeCount":95},[],{"trials":1347,"activeCount":95},[],{"intervention":1341,"totalTrials":278,"cells":1349},{"EARLY_PHASE1":1350,"PHASE1":1352,"PHASE2":1354,"PHASE3":1360,"PHASE4":1362,"NA":1364},{"trials":1351,"activeCount":95},[],{"trials":1353,"activeCount":95},[],{"trials":1355,"activeCount":95},[1356],{"nctId":1331,"briefTitle":1332,"status":101,"phases":1357,"primaryCompletion":1334,"completion":1335,"start":1336,"enrollment":1337,"conditions":1358,"interventions":1359},[86],[15,1339],[1322,1341],{"trials":1361,"activeCount":95},[],{"trials":1363,"activeCount":95},[],{"trials":1365,"activeCount":95},[],{"intervention":1367,"totalTrials":278,"cells":1368},"GHR-LRX",{"EARLY_PHASE1":1369,"PHASE1":1371,"PHASE2":1373,"PHASE3":1385,"PHASE4":1387,"NA":1389},{"trials":1370,"activeCount":95},[],{"trials":1372,"activeCount":95},[],{"trials":1374,"activeCount":95},[1375],{"nctId":1376,"briefTitle":1377,"status":101,"phases":1378,"primaryCompletion":1379,"completion":1380,"start":323,"enrollment":1381,"conditions":1382,"interventions":1384},"NCT04522180","A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly",[86],"2022-07-15","2023-05-04",34,[1383],"Acromegaly",[1367],{"trials":1386,"activeCount":95},[],{"trials":1388,"activeCount":95},[],{"trials":1390,"activeCount":95},[],{"intervention":1392,"totalTrials":278,"cells":1393},"Ganciclovir",{"EARLY_PHASE1":1394,"PHASE1":1396,"PHASE2":1398,"PHASE3":1409,"PHASE4":1411,"NA":1413},{"trials":1395,"activeCount":95},[],{"trials":1397,"activeCount":95},[],{"trials":1399,"activeCount":95},[1400],{"nctId":1401,"briefTitle":1402,"status":101,"phases":1403,"enrollment":1404,"conditions":1405,"interventions":1407},"NCT00002156","A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )",[86],194,[32,1406],"HIV Infections",[1408,1392],"Fomivirsen sodium",{"trials":1410,"activeCount":95},[],{"trials":1412,"activeCount":95},[],{"trials":1414,"activeCount":95},[],{"intervention":1416,"totalTrials":278,"cells":1417},"ISIS-APOCIIIRX",{"EARLY_PHASE1":1418,"PHASE1":1420,"PHASE2":1422,"PHASE3":1434,"PHASE4":1436,"NA":1438},{"trials":1419,"activeCount":95},[],{"trials":1421,"activeCount":95},[],{"trials":1423,"activeCount":95},[1424],{"nctId":1425,"briefTitle":1426,"status":426,"phases":1427,"primaryCompletion":1428,"completion":1429,"start":1430,"enrollment":1431,"conditions":1432,"interventions":1433},"NCT01647308","Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes",[86],"2014-01","2014-03","2012-07",15,[1244],[1416],{"trials":1435,"activeCount":95},[],{"trials":1437,"activeCount":95},[],{"trials":1439,"activeCount":95},[],{"intervention":1441,"totalTrials":278,"cells":1442},"ISIS-FGFR4RX",{"EARLY_PHASE1":1443,"PHASE1":1445,"PHASE2":1447,"PHASE3":1459,"PHASE4":1461,"NA":1463},{"trials":1444,"activeCount":95},[],{"trials":1446,"activeCount":95},[],{"trials":1448,"activeCount":95},[1449],{"nctId":1450,"briefTitle":1451,"status":101,"phases":1452,"primaryCompletion":1453,"completion":1454,"start":1455,"enrollment":11,"conditions":1456,"interventions":1458},"NCT02476019","A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients",[86],"2016-07","2016-09","2015-06",[1457],"Obesity",[1441],{"trials":1460,"activeCount":95},[],{"trials":1462,"activeCount":95},[],{"trials":1464,"activeCount":95},[],{"intervention":1466,"totalTrials":278,"cells":1467},"ISIS-GCGRRx",{"EARLY_PHASE1":1468,"PHASE1":1470,"PHASE2":1472,"PHASE3":1482,"PHASE4":1484,"NA":1486},{"trials":1469,"activeCount":95},[],{"trials":1471,"activeCount":95},[],{"trials":1473,"activeCount":95},[1474],{"nctId":1475,"briefTitle":1476,"status":101,"phases":1477,"primaryCompletion":1239,"completion":1478,"start":1479,"enrollment":1431,"conditions":1480,"interventions":1481},"NCT02824003","Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Content in Type 2 Diabetes",[86],"2017-05-22","2016-04",[1244],[1466],{"trials":1483,"activeCount":95},[],{"trials":1485,"activeCount":95},[],{"trials":1487,"activeCount":95},[],{"intervention":1489,"totalTrials":278,"cells":1490},"ISIS apoC-III Rx",{"EARLY_PHASE1":1491,"PHASE1":1493,"PHASE2":1495,"PHASE3":1504,"PHASE4":1506,"NA":1508},{"trials":1492,"activeCount":95},[],{"trials":1494,"activeCount":95},[],{"trials":1496,"activeCount":95},[1497],{"nctId":1498,"briefTitle":1499,"status":101,"phases":1500,"primaryCompletion":1428,"completion":1428,"start":1501,"enrollment":379,"conditions":1502,"interventions":1503},"NCT01529424","Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia",[86],"2012-02",[18],[1489,1489,1489],{"trials":1505,"activeCount":95},[],{"trials":1507,"activeCount":95},[],{"trials":1509,"activeCount":95},[],{"intervention":1511,"totalTrials":278,"cells":1512},"IONIS-DMPKRx",{"EARLY_PHASE1":1513,"PHASE1":1515,"PHASE2":1517,"PHASE3":1527,"PHASE4":1529,"NA":1531},{"trials":1514,"activeCount":95},[],{"trials":1516,"activeCount":95},[],{"trials":1518,"activeCount":95},[1519],{"nctId":1520,"briefTitle":1521,"status":101,"phases":1522,"primaryCompletion":1453,"completion":1523,"start":670,"enrollment":503,"conditions":1524,"interventions":1526},"NCT02312011","A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1",[85,86],"2016-08",[1525],"Myotonic Dystrophy Type 1",[1511],{"trials":1528,"activeCount":95},[],{"trials":1530,"activeCount":95},[],{"trials":1532,"activeCount":95},[],{"intervention":1534,"totalTrials":278,"cells":1535},"IONIS-GHR-LRx",{"EARLY_PHASE1":1536,"PHASE1":1538,"PHASE2":1540,"PHASE3":1552,"PHASE4":1554,"NA":1556},{"trials":1537,"activeCount":95},[],{"trials":1539,"activeCount":95},[],{"trials":1541,"activeCount":95},[1542],{"nctId":1543,"briefTitle":1544,"status":101,"phases":1545,"primaryCompletion":1546,"completion":1547,"start":1548,"enrollment":1549,"conditions":1550,"interventions":1551},"NCT03548415","Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands",[86],"2021-02-18","2021-04-02","2018-09-13",43,[1383],[1534],{"trials":1553,"activeCount":95},[],{"trials":1555,"activeCount":95},[],{"trials":1557,"activeCount":95},[],{"intervention":1559,"totalTrials":278,"cells":1560},"ISIS 443139 10 mg",{"EARLY_PHASE1":1561,"PHASE1":1563,"PHASE2":1565,"PHASE3":1581,"PHASE4":1583,"NA":1585},{"trials":1562,"activeCount":95},[],{"trials":1564,"activeCount":95},[],{"trials":1566,"activeCount":95},[1567],{"nctId":1568,"briefTitle":1569,"status":101,"phases":1570,"primaryCompletion":1571,"completion":1571,"start":1572,"enrollment":1573,"conditions":1574,"interventions":1576},"NCT02519036","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease",[85,86],"2017-11-08","2015-08-06",46,[1575],"Huntington's Disease",[1559,1577,1578,1579,1580],"ISIS 443139 30 mg","ISIS 443139 60 mg","ISIS 443139 90 mg","ISIS 443139 120 mg",{"trials":1582,"activeCount":95},[],{"trials":1584,"activeCount":95},[],{"trials":1586,"activeCount":95},[],{"intervention":1577,"totalTrials":278,"cells":1588},{"EARLY_PHASE1":1589,"PHASE1":1591,"PHASE2":1593,"PHASE3":1599,"PHASE4":1601,"NA":1603},{"trials":1590,"activeCount":95},[],{"trials":1592,"activeCount":95},[],{"trials":1594,"activeCount":95},[1595],{"nctId":1568,"briefTitle":1569,"status":101,"phases":1596,"primaryCompletion":1571,"completion":1571,"start":1572,"enrollment":1573,"conditions":1597,"interventions":1598},[85,86],[1575],[1559,1577,1578,1579,1580],{"trials":1600,"activeCount":95},[],{"trials":1602,"activeCount":95},[],{"trials":1604,"activeCount":95},[],{"intervention":1578,"totalTrials":278,"cells":1606},{"EARLY_PHASE1":1607,"PHASE1":1609,"PHASE2":1611,"PHASE3":1617,"PHASE4":1619,"NA":1621},{"trials":1608,"activeCount":95},[],{"trials":1610,"activeCount":95},[],{"trials":1612,"activeCount":95},[1613],{"nctId":1568,"briefTitle":1569,"status":101,"phases":1614,"primaryCompletion":1571,"completion":1571,"start":1572,"enrollment":1573,"conditions":1615,"interventions":1616},[85,86],[1575],[1559,1577,1578,1579,1580],{"trials":1618,"activeCount":95},[],{"trials":1620,"activeCount":95},[],{"trials":1622,"activeCount":95},[],{"intervention":1579,"totalTrials":278,"cells":1624},{"EARLY_PHASE1":1625,"PHASE1":1627,"PHASE2":1629,"PHASE3":1635,"PHASE4":1637,"NA":1639},{"trials":1626,"activeCount":95},[],{"trials":1628,"activeCount":95},[],{"trials":1630,"activeCount":95},[1631],{"nctId":1568,"briefTitle":1569,"status":101,"phases":1632,"primaryCompletion":1571,"completion":1571,"start":1572,"enrollment":1573,"conditions":1633,"interventions":1634},[85,86],[1575],[1559,1577,1578,1579,1580],{"trials":1636,"activeCount":95},[],{"trials":1638,"activeCount":95},[],{"trials":1640,"activeCount":95},[],{"intervention":1580,"totalTrials":278,"cells":1642},{"EARLY_PHASE1":1643,"PHASE1":1645,"PHASE2":1647,"PHASE3":1653,"PHASE4":1655,"NA":1657},{"trials":1644,"activeCount":95},[],{"trials":1646,"activeCount":95},[],{"trials":1648,"activeCount":95},[1649],{"nctId":1568,"briefTitle":1569,"status":101,"phases":1650,"primaryCompletion":1571,"completion":1571,"start":1572,"enrollment":1573,"conditions":1651,"interventions":1652},[85,86],[1575],[1559,1577,1578,1579,1580],{"trials":1654,"activeCount":95},[],{"trials":1656,"activeCount":95},[],{"trials":1658,"activeCount":95},[],{"intervention":1660,"totalTrials":278,"cells":1661},"ISIS CRP Rx",{"EARLY_PHASE1":1662,"PHASE1":1664,"PHASE2":1666,"PHASE3":1676,"PHASE4":1678,"NA":1680},{"trials":1663,"activeCount":95},[],{"trials":1665,"activeCount":95},[],{"trials":1667,"activeCount":95},[1668],{"nctId":1669,"briefTitle":1670,"status":101,"phases":1671,"primaryCompletion":1672,"completion":1672,"start":691,"enrollment":293,"conditions":1673,"interventions":1675},"NCT01710852","Antiarrhythmic and Symptomatic Effect of ISIS CRP Rx Targeting CRP in Paroxysmal Atrial Fibrillation",[86],"2014-04",[1674],"Paroxysmal Atrial Fibrillation",[1660],{"trials":1677,"activeCount":95},[],{"trials":1679,"activeCount":95},[],{"trials":1681,"activeCount":95},[],{"intervention":1683,"totalTrials":278,"cells":1684},"IONIS GHR-LRx",{"EARLY_PHASE1":1685,"PHASE1":1687,"PHASE2":1689,"PHASE3":1702,"PHASE4":1704,"NA":1706},{"trials":1686,"activeCount":95},[],{"trials":1688,"activeCount":95},[],{"trials":1690,"activeCount":95},[1691],{"nctId":1692,"briefTitle":1693,"status":101,"phases":1694,"primaryCompletion":1695,"completion":1696,"start":1697,"enrollment":1698,"conditions":1699,"interventions":1700},"NCT03967249","Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands",[86],"2022-03-31","2022-07-07","2019-07-25",39,[1383],[1683,1701],"Somatostatin Receptor Ligand",{"trials":1703,"activeCount":95},[],{"trials":1705,"activeCount":95},[],{"trials":1707,"activeCount":95},[],{"intervention":1701,"totalTrials":278,"cells":1709},{"EARLY_PHASE1":1710,"PHASE1":1712,"PHASE2":1714,"PHASE3":1720,"PHASE4":1722,"NA":1724},{"trials":1711,"activeCount":95},[],{"trials":1713,"activeCount":95},[],{"trials":1715,"activeCount":95},[1716],{"nctId":1692,"briefTitle":1693,"status":101,"phases":1717,"primaryCompletion":1695,"completion":1696,"start":1697,"enrollment":1698,"conditions":1718,"interventions":1719},[86],[1383],[1683,1701],{"trials":1721,"activeCount":95},[],{"trials":1723,"activeCount":95},[],{"trials":1725,"activeCount":95},[],{"intervention":1727,"totalTrials":278,"cells":1728},"ION-682884",{"EARLY_PHASE1":1729,"PHASE1":1731,"PHASE2":1733,"PHASE3":1745,"PHASE4":1747,"NA":1749},{"trials":1730,"activeCount":95},[],{"trials":1732,"activeCount":95},[],{"trials":1734,"activeCount":95},[1735],{"nctId":1736,"briefTitle":1737,"status":101,"phases":1738,"primaryCompletion":1739,"completion":1739,"start":1740,"enrollment":1741,"conditions":1742,"interventions":1744},"NCT03728634","Evaluate the Safety and Tolerability, as Well as the Pharmacokinetic and Pharmacodynamic Profiles of Single and Multiple Doses of Eplontersen Administered Subcutaneously to Healthy Volunteers and Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR ).",[85,86],"2020-02-20","2018-12-21",47,[27,1743],"hATTR Amyloidosis",[1727],{"trials":1746,"activeCount":95},[],{"trials":1748,"activeCount":95},[],{"trials":1750,"activeCount":95},[],{"intervention":1752,"totalTrials":278,"cells":1753},"ISIS CRP Rx or Placebo",{"EARLY_PHASE1":1754,"PHASE1":1756,"PHASE2":1758,"PHASE3":1768,"PHASE4":1770,"NA":1772},{"trials":1755,"activeCount":95},[],{"trials":1757,"activeCount":95},[],{"trials":1759,"activeCount":95},[1760],{"nctId":1761,"briefTitle":1762,"status":101,"phases":1763,"primaryCompletion":874,"completion":874,"start":1764,"enrollment":1765,"conditions":1766,"interventions":1767},"NCT01414101","Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Arthritis",[86],"2011-08",51,[1155],[1752],{"trials":1769,"activeCount":95},[],{"trials":1771,"activeCount":95},[],{"trials":1773,"activeCount":95},[],{"intervention":1775,"totalTrials":278,"cells":1776},"IONIS-STAT3Rx",{"EARLY_PHASE1":1777,"PHASE1":1779,"PHASE2":1781,"PHASE3":1794,"PHASE4":1796,"NA":1798},{"trials":1778,"activeCount":95},[],{"trials":1780,"activeCount":95},[],{"trials":1782,"activeCount":95},[1783],{"nctId":1784,"briefTitle":1785,"status":101,"phases":1786,"primaryCompletion":1787,"completion":1787,"start":1788,"enrollment":1286,"conditions":1789,"interventions":1793},"NCT01563302","Phase 1\u002F2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers",[85,86],"2016-03-23","2012-02-27",[1790,1791,1792],"Advanced Cancers","DLBCL","Lymphoma",[1775],{"trials":1795,"activeCount":95},[],{"trials":1797,"activeCount":95},[],{"trials":1799,"activeCount":95},[],{"intervention":1801,"totalTrials":278,"cells":1802},"IONIS DGAT2Rx",{"EARLY_PHASE1":1803,"PHASE1":1805,"PHASE2":1807,"PHASE3":1819,"PHASE4":1821,"NA":1823},{"trials":1804,"activeCount":95},[],{"trials":1806,"activeCount":95},[],{"trials":1808,"activeCount":95},[1809],{"nctId":1810,"briefTitle":1811,"status":101,"phases":1812,"primaryCompletion":1813,"completion":1813,"start":1814,"enrollment":1815,"conditions":1816,"interventions":1818},"NCT03334214","Safety, Tolerability, and Pharmacodynamics of IONIS-DGAT2Rx in Adult Patients With Type 2 Diabetes",[86],"2018-11-28","2017-11-03",44,[1817],"Hepatic Steatosis",[1801],{"trials":1820,"activeCount":95},[],{"trials":1822,"activeCount":95},[],{"trials":1824,"activeCount":95},[],{"intervention":1826,"totalTrials":278,"cells":1827},"ISIS-GCGRRx - Dose Level 1",{"EARLY_PHASE1":1828,"PHASE1":1830,"PHASE2":1832,"PHASE3":1844,"PHASE4":1846,"NA":1848},{"trials":1829,"activeCount":95},[],{"trials":1831,"activeCount":95},[],{"trials":1833,"activeCount":95},[1834],{"nctId":1835,"briefTitle":1836,"status":101,"phases":1837,"primaryCompletion":1176,"completion":1838,"start":1839,"enrollment":1840,"conditions":1841,"interventions":1842},"NCT01885260","Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes",[86],"2014-11","2013-07",77,[15],[1826,1843],"ISIS-GCGRRx - Dose Level 2",{"trials":1845,"activeCount":95},[],{"trials":1847,"activeCount":95},[],{"trials":1849,"activeCount":95},[],{"intervention":1843,"totalTrials":278,"cells":1851},{"EARLY_PHASE1":1852,"PHASE1":1854,"PHASE2":1856,"PHASE3":1862,"PHASE4":1864,"NA":1866},{"trials":1853,"activeCount":95},[],{"trials":1855,"activeCount":95},[],{"trials":1857,"activeCount":95},[1858],{"nctId":1835,"briefTitle":1836,"status":101,"phases":1859,"primaryCompletion":1176,"completion":1838,"start":1839,"enrollment":1840,"conditions":1860,"interventions":1861},[86],[15],[1826,1843],{"trials":1863,"activeCount":95},[],{"trials":1865,"activeCount":95},[],{"trials":1867,"activeCount":95},[],{"intervention":1869,"totalTrials":278,"cells":1870},"ISIS 14803, peginterferon alfa, ribavirin",{"EARLY_PHASE1":1871,"PHASE1":1873,"PHASE2":1875,"PHASE3":1885,"PHASE4":1887,"NA":1889},{"trials":1872,"activeCount":95},[],{"trials":1874,"activeCount":95},[],{"trials":1876,"activeCount":95},[1877],{"nctId":1878,"briefTitle":1879,"status":101,"phases":1880,"primaryCompletion":1881,"completion":1881,"start":1882,"enrollment":8,"conditions":1883,"interventions":1884},"NCT00062816","Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs",[85,86],"2004-01","2003-06",[1069],[1869],{"trials":1886,"activeCount":95},[],{"trials":1888,"activeCount":95},[],{"trials":1890,"activeCount":95},[],{"intervention":1892,"totalTrials":278,"cells":1893},"ISIS 333611",{"EARLY_PHASE1":1894,"PHASE1":1896,"PHASE2":1909,"PHASE3":1911,"PHASE4":1913,"NA":1915},{"trials":1895,"activeCount":95},[],{"trials":1897,"activeCount":95},[1898],{"nctId":1899,"briefTitle":1900,"status":101,"phases":1901,"primaryCompletion":1902,"completion":1903,"start":1904,"enrollment":1905,"conditions":1906,"interventions":1908},"NCT01041222","Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations",[85],"2011-12","2012-01","2010-01",33,[1907],"Familial Amyotrophic Lateral Sclerosis",[1892],{"trials":1910,"activeCount":95},[],{"trials":1912,"activeCount":95},[],{"trials":1914,"activeCount":95},[],{"trials":1916,"activeCount":95},[],{"intervention":1918,"totalTrials":278,"cells":1919},"BIIB094",{"EARLY_PHASE1":1920,"PHASE1":1922,"PHASE2":1934,"PHASE3":1936,"PHASE4":1938,"NA":1940},{"trials":1921,"activeCount":95},[],{"trials":1923,"activeCount":95},[1924],{"nctId":1925,"briefTitle":1926,"status":101,"phases":1927,"primaryCompletion":1928,"completion":1928,"start":1929,"enrollment":1930,"conditions":1931,"interventions":1933},"NCT03976349","A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease",[85],"2024-08-12","2019-08-12",62,[1932],"Parkinson's Disease",[1918],{"trials":1935,"activeCount":95},[],{"trials":1937,"activeCount":95},[],{"trials":1939,"activeCount":95},[],{"trials":1941,"activeCount":95},[],{"intervention":1943,"totalTrials":278,"cells":1944},"IONIS-ENaCRx",{"EARLY_PHASE1":1945,"PHASE1":1947,"PHASE2":1960,"PHASE3":1962,"PHASE4":1964,"NA":1966},{"trials":1946,"activeCount":95},[],{"trials":1948,"activeCount":95},[1949],{"nctId":1950,"briefTitle":1951,"status":101,"phases":1952,"primaryCompletion":1953,"completion":1953,"start":1954,"enrollment":1955,"conditions":1956,"interventions":1959},"NCT03647228","A Phase 1\u002F2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis",[85],"2020-10-13","2018-12-13",98,[1957,1958],"Healthy Subjects","Cystic Fibrosis",[1943],{"trials":1961,"activeCount":95},[],{"trials":1963,"activeCount":95},[],{"trials":1965,"activeCount":95},[],{"trials":1967,"activeCount":95},[],{"intervention":1969,"totalTrials":278,"cells":1970},"ISIS 388626",{"EARLY_PHASE1":1971,"PHASE1":1973,"PHASE2":1984,"PHASE3":1986,"PHASE4":1988,"NA":1990},{"trials":1972,"activeCount":95},[],{"trials":1974,"activeCount":95},[1975],{"nctId":1976,"briefTitle":1977,"status":101,"phases":1978,"primaryCompletion":1979,"completion":1903,"start":1980,"enrollment":1981,"conditions":1982,"interventions":1983},"NCT00836225","Safety, Tolerability and Activity Study of Multiple Doses of ISIS-SGLT2Rx in Healthy Volunteers",[85],"2011-10","2009-01",103,[15],[1969],{"trials":1985,"activeCount":95},[],{"trials":1987,"activeCount":95},[],{"trials":1989,"activeCount":95},[],{"trials":1991,"activeCount":95},[],{"intervention":1993,"totalTrials":278,"cells":1994},"ISIS 353512",{"EARLY_PHASE1":1995,"PHASE1":1997,"PHASE2":2009,"PHASE3":2011,"PHASE4":2013,"NA":2015},{"trials":1996,"activeCount":95},[],{"trials":1998,"activeCount":95},[1999],{"nctId":2000,"briefTitle":2001,"status":101,"phases":2002,"primaryCompletion":2003,"completion":2004,"start":2005,"enrollment":1981,"conditions":2006,"interventions":2008},"NCT00734240","Safety and Tolerability of Single and Multiple Doses of ISIS 353512 in Healthy Volunteers",[85],"2010-02","2010-03","2008-07",[2007],"Inflammatory Diseases",[1993,1993,1993,1993,1993,1993,1993,1993,1993,1993,1993,1993,1993,1993,1993,1993],{"trials":2010,"activeCount":95},[],{"trials":2012,"activeCount":95},[],{"trials":2014,"activeCount":95},[],{"trials":2016,"activeCount":95},[],{"intervention":2018,"totalTrials":278,"cells":2019},"ISIS 325568",{"EARLY_PHASE1":2020,"PHASE1":2022,"PHASE2":2033,"PHASE3":2035,"PHASE4":2037,"NA":2039},{"trials":2021,"activeCount":95},[],{"trials":2023,"activeCount":95},[2024],{"nctId":2025,"briefTitle":2026,"status":101,"phases":2027,"primaryCompletion":2028,"completion":2029,"start":2030,"enrollment":244,"conditions":2031,"interventions":2032},"NCT00519727","Safety Study of ISIS 325568 in Healthy Volunteers",[85],"2008-04","2008-06","2007-08",[15],[2018],{"trials":2034,"activeCount":95},[],{"trials":2036,"activeCount":95},[],{"trials":2038,"activeCount":95},[],{"trials":2040,"activeCount":95},[],{"intervention":2042,"totalTrials":278,"cells":2043},"ION537",{"EARLY_PHASE1":2044,"PHASE1":2046,"PHASE2":2056,"PHASE3":2058,"PHASE4":2060,"NA":2062},{"trials":2045,"activeCount":95},[],{"trials":2047,"activeCount":95},[2048],{"nctId":2049,"briefTitle":2050,"status":101,"phases":2051,"primaryCompletion":939,"completion":939,"start":2052,"enrollment":1431,"conditions":2053,"interventions":2055},"NCT04659096","A Study of ION537 in Patients With Molecularly Selected Advanced Solid Tumors",[85],"2021-01-05",[2054],"Advanced Solid Tumors",[2042],{"trials":2057,"activeCount":95},[],{"trials":2059,"activeCount":95},[],{"trials":2061,"activeCount":95},[],{"trials":2063,"activeCount":95},[],{"intervention":2065,"totalTrials":278,"cells":2066},"ION269",{"EARLY_PHASE1":2067,"PHASE1":2069,"PHASE2":2081,"PHASE3":2083,"PHASE4":2085,"NA":2087},{"trials":2068,"activeCount":95},[],{"trials":2070,"activeCount":95},[2071],{"nctId":2072,"briefTitle":2073,"status":426,"phases":2074,"primaryCompletion":2075,"completion":2075,"start":2076,"enrollment":278,"conditions":2077,"interventions":2080},"NCT06673069","Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)",[85],"2025-12-03","2024-12-20",[2078,2079],"Alzheimer Disease","Down Syndrome",[2065],{"trials":2082,"activeCount":95},[],{"trials":2084,"activeCount":95},[],{"trials":2086,"activeCount":95},[],{"trials":2088,"activeCount":95},[],{"intervention":2090,"totalTrials":278,"cells":2091},"IONIS ANGPTL3-LRx",{"EARLY_PHASE1":2092,"PHASE1":2094,"PHASE2":2106,"PHASE3":2108,"PHASE4":2110,"NA":2112},{"trials":2093,"activeCount":95},[],{"trials":2095,"activeCount":95},[2096],{"nctId":2097,"briefTitle":2098,"status":101,"phases":2099,"primaryCompletion":2100,"completion":2101,"start":2102,"enrollment":503,"conditions":2103,"interventions":2105},"NCT02709850","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Participants With Familial Hypercholesterolemia",[85],"2017-04-12","2017-06-26","2015-11-30",[18,2104],"Familial Hypercholesterolemia",[2090],{"trials":2107,"activeCount":95},[],{"trials":2109,"activeCount":95},[],{"trials":2111,"activeCount":95},[],{"trials":2113,"activeCount":95},[],{"intervention":2115,"totalTrials":278,"cells":2116},"IONIS-APO(a)-LRx",{"EARLY_PHASE1":2117,"PHASE1":2119,"PHASE2":2130,"PHASE3":2132,"PHASE4":2134,"NA":2136},{"trials":2118,"activeCount":95},[],{"trials":2120,"activeCount":95},[2121],{"nctId":2122,"briefTitle":2123,"status":101,"phases":2124,"primaryCompletion":2125,"completion":2125,"start":2126,"enrollment":244,"conditions":2127,"interventions":2128},"NCT02414594","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)",[85],"2016-02","2015-04",[1288],[2115,2129],"Sterile Normal Saline",{"trials":2131,"activeCount":95},[],{"trials":2133,"activeCount":95},[],{"trials":2135,"activeCount":95},[],{"trials":2137,"activeCount":95},[],{"intervention":2129,"totalTrials":278,"cells":2139},{"EARLY_PHASE1":2140,"PHASE1":2142,"PHASE2":2148,"PHASE3":2150,"PHASE4":2152,"NA":2154},{"trials":2141,"activeCount":95},[],{"trials":2143,"activeCount":95},[2144],{"nctId":2122,"briefTitle":2123,"status":101,"phases":2145,"primaryCompletion":2125,"completion":2125,"start":2126,"enrollment":244,"conditions":2146,"interventions":2147},[85],[1288],[2115,2129],{"trials":2149,"activeCount":95},[],{"trials":2151,"activeCount":95},[],{"trials":2153,"activeCount":95},[],{"trials":2155,"activeCount":95},[],{"intervention":2157,"totalTrials":278,"cells":2158},"Ionis AGT-LRx",{"EARLY_PHASE1":2159,"PHASE1":2161,"PHASE2":2172,"PHASE3":2174,"PHASE4":2176,"NA":2178},{"trials":2160,"activeCount":95},[],{"trials":2162,"activeCount":95},[2163],{"nctId":2164,"briefTitle":2165,"status":101,"phases":2166,"primaryCompletion":2167,"completion":2168,"start":2169,"enrollment":1930,"conditions":2170,"interventions":2171},"NCT03101878","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ionis AGT-LRx in Healthy Volunteers",[85],"2018-03-29","2018-08-01","2017-04-05",[27],[2157],{"trials":2173,"activeCount":95},[],{"trials":2175,"activeCount":95},[],{"trials":2177,"activeCount":95},[],{"trials":2179,"activeCount":95},[],{"intervention":2181,"totalTrials":278,"cells":2182},"APOC-III-L-Rx",{"EARLY_PHASE1":2183,"PHASE1":2185,"PHASE2":2196,"PHASE3":2198,"PHASE4":2200,"NA":2202},{"trials":2184,"activeCount":95},[],{"trials":2186,"activeCount":95},[2187],{"nctId":2188,"briefTitle":2189,"status":101,"phases":2190,"primaryCompletion":2191,"completion":2191,"start":1454,"enrollment":2192,"conditions":2193,"interventions":2195},"NCT02900027","Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Healthy Volunteers With Elevated Triglycerides",[85],"2018-04-30",56,[2194],"Elevated Triglycerides (TG)",[2181],{"trials":2197,"activeCount":95},[],{"trials":2199,"activeCount":95},[],{"trials":2201,"activeCount":95},[],{"trials":2203,"activeCount":95},[],{"intervention":2205,"totalTrials":278,"cells":2206},"ION547",{"EARLY_PHASE1":2207,"PHASE1":2209,"PHASE2":2219,"PHASE3":2221,"PHASE4":2223,"NA":2225},{"trials":2208,"activeCount":95},[],{"trials":2210,"activeCount":95},[2211],{"nctId":2212,"briefTitle":2213,"status":101,"phases":2214,"primaryCompletion":2215,"completion":2215,"start":2216,"enrollment":503,"conditions":2217,"interventions":2218},"NCT04934891","A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ION547",[85],"2022-09-14","2021-03-24",[27],[2205],{"trials":2220,"activeCount":95},[],{"trials":2222,"activeCount":95},[],{"trials":2224,"activeCount":95},[],{"trials":2226,"activeCount":95},[],{"intervention":2228,"totalTrials":278,"cells":2229},"IONIS MAPTRx",{"EARLY_PHASE1":2230,"PHASE1":2232,"PHASE2":2243,"PHASE3":2245,"PHASE4":2247,"NA":2249},{"trials":2231,"activeCount":95},[],{"trials":2233,"activeCount":95},[2234],{"nctId":2235,"briefTitle":2236,"status":101,"phases":2237,"primaryCompletion":2238,"completion":2238,"start":2239,"enrollment":1573,"conditions":2240,"interventions":2242},"NCT03186989","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease",[85],"2022-05-12","2017-10-12",[2241],"Mild Alzheimer's Disease",[2228],{"trials":2244,"activeCount":95},[],{"trials":2246,"activeCount":95},[],{"trials":2248,"activeCount":95},[],{"trials":2250,"activeCount":95},[],{"intervention":2252,"totalTrials":278,"cells":2253},"IONIS FXI-LRx",{"EARLY_PHASE1":2254,"PHASE1":2256,"PHASE2":2266,"PHASE3":2268,"PHASE4":2270,"NA":2272},{"trials":2255,"activeCount":95},[],{"trials":2257,"activeCount":95},[2258],{"nctId":2259,"briefTitle":2260,"status":101,"phases":2261,"primaryCompletion":2262,"completion":2262,"start":2263,"enrollment":235,"conditions":2264,"interventions":2265},"NCT03582462","A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of IONIS FXI-LRx in up to 84 Healthy Volunteers",[85],"2019-04-26","2018-07-09",[29],[2252],{"trials":2267,"activeCount":95},[],{"trials":2269,"activeCount":95},[],{"trials":2271,"activeCount":95},[],{"trials":2273,"activeCount":95},[],{"intervention":2275,"totalTrials":278,"cells":2276},"ION251",{"EARLY_PHASE1":2277,"PHASE1":2279,"PHASE2":2291,"PHASE3":2293,"PHASE4":2295,"NA":2297},{"trials":2278,"activeCount":95},[],{"trials":2280,"activeCount":95},[2281],{"nctId":2282,"briefTitle":2283,"status":101,"phases":2284,"primaryCompletion":2285,"completion":2285,"start":2286,"enrollment":326,"conditions":2287,"interventions":2290},"NCT04398485","A Study of ION251 Administered to Patients With Relapsed\u002FRefractory Multiple Myeloma",[85],"2024-09-30","2021-01-20",[2288,2289],"Relapsed Multiple Myeloma","Refractory Multiple Myeloma",[2275],{"trials":2292,"activeCount":95},[],{"trials":2294,"activeCount":95},[],{"trials":2296,"activeCount":95},[],{"trials":2298,"activeCount":95},[],{"intervention":2300,"totalTrials":278,"cells":2301},"Pelacarsen",{"EARLY_PHASE1":2302,"PHASE1":2304,"PHASE2":2314,"PHASE3":2316,"PHASE4":2318,"NA":2320},{"trials":2303,"activeCount":95},[],{"trials":2305,"activeCount":95},[2306],{"nctId":2307,"briefTitle":2308,"status":101,"phases":2309,"primaryCompletion":2310,"completion":2310,"start":2311,"enrollment":430,"conditions":2312,"interventions":2313},"NCT05337878","A Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pelacarsen (ISIS 681257) in Healthy Japanese Participants",[85],"2019-12-18","2018-10-15",[29],[2300],{"trials":2315,"activeCount":95},[],{"trials":2317,"activeCount":95},[],{"trials":2319,"activeCount":95},[],{"trials":2321,"activeCount":95},[],{"intervention":649,"totalTrials":278,"cells":2323},{"EARLY_PHASE1":2324,"PHASE1":2326,"PHASE2":2332,"PHASE3":2334,"PHASE4":2336,"NA":2338},{"trials":2325,"activeCount":95},[],{"trials":2327,"activeCount":95},[2328],{"nctId":640,"briefTitle":641,"status":101,"phases":2329,"primaryCompletion":643,"completion":643,"start":644,"enrollment":645,"conditions":2330,"interventions":2331},[85],[647],[633,649],{"trials":2333,"activeCount":95},[],{"trials":2335,"activeCount":95},[],{"trials":2337,"activeCount":95},[],{"trials":2339,"activeCount":95},[],{"intervention":2341,"totalTrials":278,"cells":2342},"IONIS TMPRSS6-Lrx",{"EARLY_PHASE1":2343,"PHASE1":2345,"PHASE2":2357,"PHASE3":2359,"PHASE4":2361,"NA":2363},{"trials":2344,"activeCount":95},[],{"trials":2346,"activeCount":95},[2347],{"nctId":2348,"briefTitle":2349,"status":101,"phases":2350,"primaryCompletion":2351,"completion":2351,"start":2352,"enrollment":2353,"conditions":2354,"interventions":2356},"NCT03165864","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered Subcutaneously to Healthy Volunteers",[85],"2018-09-25","2017-05-09",36,[2355],"Thalassemia",[2341],{"trials":2358,"activeCount":95},[],{"trials":2360,"activeCount":95},[],{"trials":2362,"activeCount":95},[],{"trials":2364,"activeCount":95},[],{"intervention":149,"totalTrials":30,"cells":2366},{"EARLY_PHASE1":2367,"PHASE1":2369,"PHASE2":2371,"PHASE3":2373,"PHASE4":2404,"NA":2406},{"trials":2368,"activeCount":95},[],{"trials":2370,"activeCount":95},[],{"trials":2372,"activeCount":95},[],{"trials":2374,"activeCount":95},[2375,2390,2400],{"nctId":2376,"briefTitle":2377,"status":101,"phases":2378,"primaryCompletion":2379,"completion":2380,"start":2381,"enrollment":2382,"conditions":2383,"interventions":2389},"NCT02175004","Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)",[87],"2020-09-11","2021-01-07","2014-06-26",135,[2384,2385,2386,2387,2388],"FAP","Familial Amyloid Polyneuropathy","TTR","Transthyretin","Amyloidosis",[149],{"nctId":2391,"briefTitle":2392,"status":101,"phases":2393,"primaryCompletion":2394,"completion":2395,"start":2396,"enrollment":2397,"conditions":2398,"interventions":2399},"NCT01737398","Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy",[86,87],"2017-03-03","2017-11-07","2013-03-15",173,[2384,2385,2386,2387,2388],[149],{"nctId":140,"briefTitle":141,"status":101,"phases":2401,"primaryCompletion":143,"completion":144,"start":145,"enrollment":146,"conditions":2402,"interventions":2403},[87],[128],[149,48],{"trials":2405,"activeCount":95},[],{"trials":2407,"activeCount":95},[2408],{"nctId":2409,"briefTitle":2410,"status":254,"phases":2411,"conditions":2412,"interventions":2414},"NCT03400098","ATTR Expanded Access Program (EAP) by Ionis",[],[2413],"Amyloidosis, Hereditary",[149],{"intervention":1408,"totalTrials":30,"cells":2416},{"EARLY_PHASE1":2417,"PHASE1":2419,"PHASE2":2421,"PHASE3":2433,"PHASE4":2435,"NA":2437},{"trials":2418,"activeCount":95},[],{"trials":2420,"activeCount":95},[],{"trials":2422,"activeCount":95},[2423,2427],{"nctId":1401,"briefTitle":1402,"status":101,"phases":2424,"enrollment":1404,"conditions":2425,"interventions":2426},[86],[32,1406],[1408,1392],{"nctId":2428,"briefTitle":2429,"status":101,"phases":2430,"conditions":2431,"interventions":2432},"NCT00002356","The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytomegalovirus (CMV) of the Eyes",[86],[32,1406],[1408],{"trials":2434,"activeCount":95},[],{"trials":2436,"activeCount":95},[],{"trials":2438,"activeCount":95},[2439,2445],{"nctId":2440,"briefTitle":2441,"status":101,"phases":2442,"enrollment":244,"conditions":2443,"interventions":2444},"NCT00002355","A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalovirus (CMV) of the Eyes",[89],[32,1406],[1408],{"nctId":2446,"briefTitle":2447,"status":101,"phases":2448,"conditions":2449,"interventions":2450},"NCT00002187","A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis",[89],[32,1406],[1408]]